FiercePharma says: Pfizer reported net income of $2.5 billion, or 31 cents a share, during the second quarter, representing an increase of nine percent compared with the same quarter last year. Although sales of blockbuster Lipitor, which faces looming generic competition, continued to slow, Pfizer got a boost from its acquisition of Wyeth. Pfizer's revenue increased 58 percent to $17.3 billion. Revenues were favorably impacted by $5.4 billion, or 50 percent, due to the addition of the legacy Wyeth products, by $315 million, or three percent, due to legacy Pfizer products, and by $584 million, or five percent, due to foreign exchange, the company says in a statement.

Highlights

• Second-Quarter 2010 Revenues of $17.3 Billion
• Second-Quarter 2010 Reported Diluted EPS⁽¹⁾ of $0.31, Adjusted Diluted EPS⁽²⁾ of $0.62
• Reaffirms 2010 Financial Guidance and 2012 Financial Targets
• Strong Quarterly Performance Reflects More Balanced Business Mix and Product Portfolio

See Pfizer's current stock quote from CNN Money

Pfizer's website: http://www.pfizer.com/
Full earnings: Pfizer's earnings

Related Articles:
Pfizer takes on security screenings for air cargo
Pfizer aims for 6 more months of Viagra
Jeffrey Kindler - 2009 CEO Pay
Key drugs for AZ, Pfizer get generic rivals
Pfizer faces trials in hundreds of Prempro suits
Pfizer manufacturing overhaul claims 8 plants, 6,000 jobs
Pfizer says it's a "golden age" for drug discovery